Autek China Inc
SZSE:300595
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (20.3), the stock would be worth ¥18.83 (32% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 15.4 | ¥14.3 |
0%
|
| 3-Year Average | 20.3 | ¥18.83 |
+32%
|
| 5-Year Average | 28.2 | ¥26.17 |
+83%
|
| Industry Average | 26.2 | ¥24.32 |
+70%
|
| Country Average | 28.8 | ¥26.75 |
+87%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥9.3B
|
/ |
Jan 2026
¥634.5m
|
= |
|
|
¥9.3B
|
/ |
Dec 2026
¥952.7m
|
= |
|
|
¥9.3B
|
/ |
Dec 2027
¥1B
|
= |
|
|
¥9.3B
|
/ |
Dec 2028
¥997.9m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Autek China Inc
SZSE:300595
|
12.8B CNY | 15.4 | 26.7 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 28 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 14.4 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 12.5 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 14.3 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 11.5 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 16.8 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 23.8 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 20.9 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -80.8 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Autek China Inc
Glance View
Autek China Inc. stands as an emblematic figure in the dynamic landscape of medical devices and biotechnology in China. Rooted in its mission to innovate within the realms of diagnostic imaging and therapeutic ultrasound equipment, the company has maneuvered through this niche market by leveraging both cutting-edge technology and strategic partnerships. Autek's portfolio includes a range of high-quality ultrasound machines and imaging solutions that cater to the rapidly evolving needs of hospitals and clinics. By capitalizing on the growing demand for advanced healthcare services in China, Autek has tailored its product offerings to resonate with local market needs while maintaining competitive pricing strategies. This keen understanding of market dynamics allows Autek to maintain a robust sales pipeline and forge sturdy relationships within the medical community, driving its revenue growth engine. The company's operational blueprint hinges on an impressive blend of research-driven innovation and effective distribution networks. Autek continually invests in research and development, aspiring to push technological boundaries and uphold its reputation as a pioneer in the medical imaging sector. This investment lays the groundwork for creating state-of-the-art products that are not only technologically advanced but also user-friendly for medical professionals. Autek's adeptness at navigating regulatory landscapes ensures smooth market entry and expansion for its offerings. Furthermore, its strategic alliances with healthcare providers and government entities enhance its distribution network, ensuring that its products reach a wide spectrum of healthcare institutions across China. Autek makes its money by selling its technologically advanced and reliable devices, as well as providing ongoing support and maintenance services, forming the backbone of its revenue model and securing its position in the competitive arena.